curasan AG

  • WKN: A2YPGM
  • ISIN: DE000A2YPGM4
  • Land: Deutschland

Nachricht vom 01.10.2019 | 14:48

curasan launches product for the treatment of the spinal facet syndrome


DGAP-Media / 01.10.2019 / 14:48

curasan launches product for the treatment of the spinal facet syndrome

- curasan receives CE clearance for Spinevisc(R) Hyaluronic Acid for the treatment of spinal facet joint arthrosis

- Extended reach to new target groups in the Spine, Neuroradiology and Interventional Pain Therapy market


Kleinostheim, October 1st, 2019 - curasan AG, Germany, a leading specialist for medical products in the field of orthobiologics and interventional pain management, launches Spinevisc(R), a biomimetic hyaluronic acid with a medium molecular weight similar to the body's own synovial fluids, dedicated for the treatment of the widespread facet syndrome (facet joint arthrosis).

"The launch of Spinevisc(R) sets another milestone in the history of curasan", states Torben Sorensen, new CEO of curasan. "Despite the currently challenging market and regulatory environment, our interdisciplinary team of Marketing, Medical Affairs and Regulatory specialists have managed to bring a product to market that is dedicated to treat the painful symptoms of the widespread facet syndrome."

"Spinevisc(R) will allow curasan to extend its reach and to address new target groups such as specialized Neuroradiologists and Interventional Pain Therapists, as well as Spine surgeons, thus allowing the company in entering entirely new distribution channels and an untouched market segment", states Gregor Siebert, Director of Marketing and Sales.

"With over a decade experience in arthrosis management with curasan's proprietary hyaluronic acid formula, it was a logical step for us to further focus on how we could possibly address the needs of a minimally-invasive, yet safe and easy-to-apply solution in treating back pain caused by the facet syndrome", adds Florian Früh, Head of Product Management.

curasan will launch Spinevisc(R) during the German Orthopedic and Traumatology Congress (DKOU), to be held between October 22-25 in Berlin, Germany, followed by the Spine Interventional Neuroradiology Symposium of the European Society of Neuroradiology (ESNR), to be held from October 25-27 in Malta.


Contact curasan AG:
Andrea Weidner
IR & Corporate Communications
pr@curasan.com


Contact for product related requests:
Florian Früh
Head of Product Management
florian.frueh@curasan.com

About curasan AG:
curasan develops, manufactures and markets biomaterials and medical devices in the field of bone and tissue regeneration, wound healing and osteoarthritis therapy. As a pioneer and global technology leader in the growing field of regenerative medicine, curasan is specialized primarily on biomimetic bone grafting materials for dental, oral/maxillofacial, orthopedic and spinal applications, i.e. materials mimicking biological structures. Numerous patents and a broad record of scientific publications demonstrate the clinical success of the products and the highly innovative strength of curasan.



End of Media Release


Issuer: curasan AG
Key word(s): Health

01.10.2019 Dissemination of a Press Release, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

Interview im Fokus

Mountain Alliance: „Großer Digitalisierungsschub“

Furioses Börsendebüt für den Datenbankspezialisten Exasol. Einer der Profiteure: Die Münchner Beteiligungsgesellschaft Mountain Alliance AG (MA, ISIN DE000A12UK08), die auch nach einem Teilexit noch rund 2% an Exasol hält. Aktuell notiert die MA-Aktie rund 30 % unter dem NAV. Financial.de sprach mit MA-CEO Daniel Wild über die stärksten Digitalisierungstrends, die kritische Größe von 100 Mio. Euro Börsenwert, den neuen Investor und weitere Aktienkäufe.

GBC-Fokusbox

Aves One AG: Kursziel 13,60 €

Die Aves One AG ist auch in der Corona-Krise als Bestandshalter von langlebigen Logistik-Assets mit langfristigen Mietverträgen gut aufgestellt. Das Unternehmen hat als Guidance einen Umsatz und ein EBITDA mindestens auf Vorjahresniveau verkündet. Unseres Erachtens sollte dies auch ohne Zukäufe gut machbar sein, da die im abgelaufenen Geschäftsjahr 2019 erworbenen Assets bereits zu einer höheren Umsatzbasis führen sollten. Auf Basis unseres DCF-Modells haben wir ein Kursziel in Höhe von 13,60 € ermittelt und vergeben ein KAUFEN-Rating.

News im Fokus

Deutsche Lufthansa AG: Einigung über Lufthansa Stabilisierungspaket

30. Mai 2020, 00:04

Aktuelle Research-Studie

2G Energy AG

Original-Research: 2G Energy AG (von First Berlin Equity Research GmbH): Hinzufügen

29. Mai 2020